OSUR OraSure Technologies Inc.

OraSure Technologies to Present at the Raymond James 42nd Annual Institutional Investors Conference

OraSure Technologies to Present at the Raymond James 42nd Annual Institutional Investors Conference

BETHLEHEM, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Raymond James 42nd Annual Institutional Investors Conference. The conference will be simultaneously webcast over the Internet.

Dr. Tang is scheduled to speak on March 3, 2021, at approximately 10:00 AM Eastern Standard Time (7:00 AM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site,  and clicking on the Investor Relations link. A replay of the webcast will be available on OraSure Technologies’ web site for 14 days. Alternatively, you can access the live webcast of the presentation via the following link: .

About OraSure Technologies

OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit .

Company contacts:

Sam Martin

Argot Partners

212-600-1902

Jeanne Mell

VP Corporate Communications

484-353-1575





EN
24/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OraSure Technologies Inc.

 PRESS RELEASE

OraSure Reports Q4 ‘23 Revenue of $75.9 Million

OraSure Reports Q4 ‘23 Revenue of $75.9 Million Q4 GAAP EPS of $0.27; Q4 Non-GAAP EPS of $0.22 Grew cash balance to $290.4 million as of December 31, 2023 Enters U.S. Syphilis testing market via strategic distribution agreement with Diagnostics Direct BETHLEHEM, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services, today announced its financial results for the three months ended December 31, 2023. “We made meaningful progress ...

 PRESS RELEASE

OraSure to Announce Fourth Quarter 2023 Financial Results and Host Ear...

OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th BETHLEHEM, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2023 financial results and certain business developments for 5 p.m. ET on Tuesday, Feb. 27, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. ...

 PRESS RELEASE

OraSure Technologies, Inc. Secures Strategic Distribution Rights and I...

OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company  The relationship expands OraSure’s innovation pipeline with access to a broad portfolio of key Sapphiros products in development. Distribution of Sapphiros’ products is expected to accelerate OraSure’s core revenue growth rate beginning in 2025. BETHLEHEM, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and ana...

 PRESS RELEASE

OraSure to Participate in Upcoming Investor Conferences

OraSure to Participate in Upcoming Investor Conferences BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the company is scheduled to participate in the following investor conferences: Stephens Annual Investment Conference on Wednesday, November 15, with a Q&A session scheduled for 2 p.m. ETEvercore ISI Annual HealthCONx Conference on Tuesday, November 28, with a Q&A session scheduled for 3 p.m. ET ...

 PRESS RELEASE

OraSure Reports Q3 ‘23 Revenue of $89.2 Million; Core Revenue Grows 7%...

OraSure Reports Q3 ‘23 Revenue of $89.2 Million; Core Revenue Grows 7% Year-over-Year Q3 GAAP EPS of $0.15; Q3 Non-GAAP EPS of $0.27 Grew cash balance to $224.9 million as of September 30, 2023 BETHLEHEM, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended September 30, 2023. “We continue to make progress on our transformation journey by ‘innovating and operatin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch